JP2023518443A5 - - Google Patents
Info
- Publication number
- JP2023518443A5 JP2023518443A5 JP2022556175A JP2022556175A JP2023518443A5 JP 2023518443 A5 JP2023518443 A5 JP 2023518443A5 JP 2022556175 A JP2022556175 A JP 2022556175A JP 2022556175 A JP2022556175 A JP 2022556175A JP 2023518443 A5 JP2023518443 A5 JP 2023518443A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010196689 | 2020-03-19 | ||
| CN202010196689.5 | 2020-03-19 | ||
| PCT/CN2021/081841 WO2021185362A1 (zh) | 2020-03-19 | 2021-03-19 | 白介素2突变体及其用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518443A JP2023518443A (ja) | 2023-05-01 |
| JPWO2021185362A5 JPWO2021185362A5 (https=) | 2024-04-02 |
| JP2023518443A5 true JP2023518443A5 (https=) | 2024-04-02 |
Family
ID=77768025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556175A Pending JP2023518443A (ja) | 2020-03-19 | 2021-03-19 | インターロイキン２変異体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230174604A1 (https=) |
| EP (1) | EP4122951A4 (https=) |
| JP (1) | JP2023518443A (https=) |
| KR (1) | KR20220155317A (https=) |
| CN (2) | CN121574230A (https=) |
| AU (1) | AU2021237518B2 (https=) |
| CA (1) | CA3175728A1 (https=) |
| TW (1) | TWI834031B (https=) |
| WO (1) | WO2021185362A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3854805A4 (en) | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NOVEL INTERLEUKIN 2 AND ITS USE |
| WO2020057646A1 (zh) | 2018-09-21 | 2020-03-26 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| JP2023518434A (ja) * | 2020-03-19 | 2023-05-01 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | インターロイキン２変異体およびその使用 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| KR20240082364A (ko) * | 2021-09-22 | 2024-06-10 | 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 | 인터루킨-2 돌연변이 및 이의 융합 단백질 |
| EP4460512A4 (en) * | 2022-01-07 | 2026-01-14 | Cure Genetics Co Ltd | NEW INTERLEUKIN-2 POLYPEPTIDES |
| US20250215452A1 (en) | 2022-03-25 | 2025-07-03 | Universität Zürich | Adenoviral Mediated Targeting of Activated Immune Cells |
| CN114853909A (zh) * | 2022-05-13 | 2022-08-05 | 南京吉盛澳玛生物医药有限公司 | 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途 |
| CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
| KR102629162B1 (ko) | 2022-11-04 | 2024-01-29 | 한국기초과학지원연구원 | 바이오의약품 품질관리를 위한 잔류 숙주세포 단백질 정량 분석 방법 및 시스템 |
| WO2024146575A1 (zh) * | 2023-01-04 | 2024-07-11 | 北京晶泰科技有限公司 | 白细胞介素-2变体及其应用 |
| CN118680877A (zh) * | 2023-03-21 | 2024-09-24 | 信达生物制药(苏州)有限公司 | 抗pd-1与突变il-2免疫缀合物制剂 |
| WO2025010341A2 (en) * | 2023-07-05 | 2025-01-09 | The Trustees Of Dartmouth College | Cytokine hybrid proteins and methods related thereto |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| NZ234674A (en) * | 1989-08-02 | 1992-02-25 | Seragen Inc | Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6960652B2 (en) * | 1999-03-30 | 2005-11-01 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| BRPI0508470A (pt) * | 2004-03-05 | 2007-07-31 | Chiron Corp | sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
| HUE029139T2 (hu) * | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| CN104231068A (zh) * | 2014-01-27 | 2014-12-24 | 苏州发士达生物科技有限公司 | 人白细胞介素ii突变体及其应用 |
| KR102042246B1 (ko) * | 2014-02-06 | 2019-11-28 | 에프. 호프만-라 로슈 아게 | 인터류킨-2 융합 단백질 및 이의 용도 |
| WO2015164815A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| MX2021000801A (es) * | 2018-07-24 | 2021-04-12 | BioNTech SE | Agonistas de il2. |
| WO2020057646A1 (zh) * | 2018-09-21 | 2020-03-26 | 信达生物制药(苏州)有限公司 | 新型白介素2及其用途 |
| EP3854805A4 (en) * | 2018-09-21 | 2022-08-24 | Innovent Biologics (Suzhou) Co., Ltd. | NOVEL INTERLEUKIN 2 AND ITS USE |
| JP2023518434A (ja) * | 2020-03-19 | 2023-05-01 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | インターロイキン２変異体およびその使用 |
| EP4273161A4 (en) * | 2020-12-31 | 2025-04-02 | Innovent Biologics (Suzhou) Co., Ltd. | Protein with heterodimeric antibody FC and manufacturing method therefor |
-
2021
- 2021-03-19 AU AU2021237518A patent/AU2021237518B2/en active Active
- 2021-03-19 WO PCT/CN2021/081841 patent/WO2021185362A1/zh not_active Ceased
- 2021-03-19 CN CN202511440514.3A patent/CN121574230A/zh active Pending
- 2021-03-19 CN CN202180021829.8A patent/CN115315437B/zh active Active
- 2021-03-19 EP EP21770699.3A patent/EP4122951A4/en active Pending
- 2021-03-19 JP JP2022556175A patent/JP2023518443A/ja active Pending
- 2021-03-19 KR KR1020227034881A patent/KR20220155317A/ko active Pending
- 2021-03-19 CA CA3175728A patent/CA3175728A1/en active Pending
- 2021-03-19 TW TW110110009A patent/TWI834031B/zh active
- 2021-03-19 US US17/911,922 patent/US20230174604A1/en active Pending